Multiple myeloma trials in Spain

In Spain 82 Also abroad 704

82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Barcelona, Madrid
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 3Taking people
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Where
Badalona, Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla
Age
18 years and over
People
206 worldwide
Run by
Janssen Cilag International
See details and how to join2025-523815-12-00 · EU 2025-523815-12-00
Phase 2/3Taking people
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, León, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Valencia
Age
18 years and over
People
680 worldwide
Run by
AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Badalona, Madrid, Pamplona, Salamanca, Santander, Seville
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
A Coruña, Badalona, Barcelona, Cáceres, Donostia, Granada, Jerez de la Frontera, León, Lugo, Madrid, Málaga, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Badalona, Barcelona, Elche, Madrid, Santander
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 2Not yet taking people in Spain
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Where
Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Lugo, Madrid, Marbella, Murcia, Oviedo, Palma, Pamplona, Salamanca, Santander, Valencia, Vitoria
Age
18 years and over
People
60
Run by
Fundacion PETHEMA
See details and how to join2026-526352-31-00 · EU 2026-526352-31-00
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Madrid, Marbella, Palma, Salamanca, Valencia
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Badalona, Barcelona, Madrid, Marbella, Pamplona, Salamanca
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Not yet taking people in Spain
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Badalona, Barcelona, Madrid, Murcia, Salamanca, Santander, Sevilla
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
No phaseTaking people
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
Where
Madrid
Age
18 years and over
People
32
Run by
Universidad Complutense de Madrid
See details and how to joinNCT07312942
No phaseTaking people
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
Where
Madrid
Age
18 years and over
People
26
Run by
Universidad Complutense de Madrid
See details and how to joinNCT07376733
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 2Taking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Badalona, Barcelona, Jerez de la Frontera, Madrid, Murcia, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00
Phase 1Taking people
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Where
Barcelona, Salamanca
Age
18 years and over
People
276 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 2Enrolling by invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Where
Barcelona
Age
1 year and over
People
500 worldwide
Run by
Autolus Limited
See details and how to joinNCT03628612
Phase 1/2Taking people
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Where
Barcelona, Madrid, Murcia, Palma, Sevilla
Age
18 years and over
People
78 worldwide
Run by
Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00
Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Barcelona
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 2Taking people
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Where
Barcelona, León, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
123 worldwide
Run by
Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00
Phase 3Not yet taking people in Spain
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Salamanca, Santander
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
Phase 1Not yet taking people in Spain
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
Where
Barcelona, Salamanca, Sevilla
Age
18 years and over
People
25 worldwide
Run by
TOLREMO therapeutics AG
See details and how to join2025-523536-39-00 · EU 2025-523536-39-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Ávila, Granada, Madrid, Málaga, Valencia, Vigo
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318